The drug, Palforzia, is taken daily in a regimen known as oral immunotherapy that aims to blunt the immune system's overreaction to peanuts. Though the treatment is not a cure and doesn't work for everyone, a panel of experts recommended that the Food and Drug Administration OK the drug. A decision could come by January. In other news from the FDA: more blood pressure medicines are recalled.
from Kaiser Health News https://ift.tt/2kQPuzJ
September 24, 2019
Rose
Health News, Kaiser Health News
No comments
Related Posts:
Americans Urged To Carry Naloxone. So What Is It, Where Can You Get It, And What Do You Do If It Fails?Following the surgeon general's rare public health advisory, The New York Times offers a look at common questions surrounding the anti-overdose medication. In other news on the epidemic: Congress is wrapping up work on legisl… Read More
Clinic CEO Facing Fraud, Bribery Charges Calls His Treatment ‘Miraculous.’ Doctors, Medicare Beg To DisagreeG. Ford Gilbert's IV insulin infusions for diabetes wounds have been called scams, but still his nationwide system of clinics that offer the procedures has been thriving. from Kaiser Health News https://ift.tt/2GNmRJm … Read More
Iowans Being Denied For Medical Devices In What Critics See As Latest Failure Of Privatized Medicaid SystemSince then-Gov. Terry Branstad transferred management of the state’s Medicaid program to for-profit companies back in April 2016, the system has come under fire from critics. from Kaiser Health News https://ift.tt/2ExpVar … Read More
Virginia Republicans’ Resistance To Expanding Medicaid Starting To CrackTwo Republican state senators said this week they would accept some form of broader Medicaid benefits. The issue has sparked a fiery debate in the state, with the Senate blocking the House's attempts to expand the program. La… Read More
Pharma’s Defeat In Doughnut Hole Battle Possible Harbinger Of Things To Come For Powerful IndustryDespite an intense lobbying push, drugmakers weren't able to convince lawmakers to let them off the hook for beneficiaries that fall into the doughtnut hole, raising questions about the industry's current clout. Meanwhile, a … Read More
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment